%0 Journal Article
%T Six-Month Clinical and Angiographic Results of Paclitaxel Eluting Simpax Stent
%A Mehmet Muhsin T¨¹rkmen
%A M¨¹sl¨¹m £¿ahin
%A Serdar Demir
%A Mehmet Vefik Yaz£¿c£¿o£¿lu
%J Ko£¿uyolu Kalp Dergisi
%D 2012
%I Bilimsel Tip Yayinevi
%X Introduction: We aimed to evaluate the safety and efficacy of the simpax stent in the treatmentof different patient groups.Patients and Methods: Forty-five patients were treated with the simpax stent. Of these patients,23 patients gave consent for six months of follow-up by quantitative coronary angiography (QSA)and six patients were evaluated by exercise electrocardiographic test. Only the patients havinglesions with stenosis > 50% of diameter and lengths > 16 mm with reference diameters < 2.75mm were included.Results: The device success rate was 100% and procedure success rate was 97.7%. The meanstent length was 24.6 ¡À 7.3 mm and stent size was 2.54 ¡À 0.24 mm. The overall six months incidenceof major adverse cardiac events (MACE) was 8.8%. MACE was consisted of two casesof non-Q wave myocardial infarction and two cases of repeated revascularization of the targetlesion. MACE rate was higher in chronic total occlusion (CTO) group than non-CTO group (respectively33.3% and 5.1). Also when compared to stent size, MACE rate was 25% in < 2.5 mm,0% ¡Ý 2.5 mm. The QSA results at six months showed in-stent late lumen loss witha diameter of0.25 ¡À 0.15 mm in 17 patients.Conclusion: The six month results in this study demonsrated excellent procedural and devicesuccess. Simpax stent was associated with a low in-stent late lumen loss. Also this study showedsimpax stent was a safe and effective device in non-CTO group with stent size ¡Ý 2.5 mm.
%K Drug eluting stents
%K paclitaxel
%K coronary restenosis.
%U http://www.kosuyolukalpdergisi.com/managete/fu_folder/2012-2/2012-15-02-060-064.pdf